\documentclass[11pt,twoside]{article}\makeatletter \IfFileExists{xcolor.sty}% {\RequirePackage{xcolor}}% {\RequirePackage{color}} \usepackage{colortbl} \usepackage{wrapfig} \usepackage{ifxetex} \ifxetex \usepackage{fontspec} \usepackage{xunicode} \catcode`⃥=\active \def⃥{\textbackslash} \catcode`❴=\active \def❴{\{} \catcode`❵=\active \def❵{\}} \def\textJapanese{\fontspec{Noto Sans CJK JP}} \def\textChinese{\fontspec{Noto Sans CJK SC}} \def\textKorean{\fontspec{Noto Sans CJK KR}} \setmonofont{DejaVu Sans Mono} \else \IfFileExists{utf8x.def}% {\usepackage[utf8x]{inputenc} \PrerenderUnicode{–} }% {\usepackage[utf8]{inputenc}} \usepackage[english]{babel} \usepackage[T1]{fontenc} \usepackage{float} \usepackage[]{ucs} \uc@dclc{8421}{default}{\textbackslash } \uc@dclc{10100}{default}{\{} \uc@dclc{10101}{default}{\}} \uc@dclc{8491}{default}{\AA{}} \uc@dclc{8239}{default}{\,} \uc@dclc{20154}{default}{ } \uc@dclc{10148}{default}{>} \def\textschwa{\rotatebox{-90}{e}} \def\textJapanese{} \def\textChinese{} \IfFileExists{tipa.sty}{\usepackage{tipa}}{} \fi \def\exampleFont{\ttfamily\small} \DeclareTextSymbol{\textpi}{OML}{25} \usepackage{relsize} \RequirePackage{array} \def\@testpach{\@chclass \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else \ifnum \@lastchclass=7 5 \else \ifnum \@lastchclass=8 \tw@ \else \ifnum \@lastchclass=9 \thr@@ \else \z@ \ifnum \@lastchclass = 10 \else \edef\@nextchar{\expandafter\string\@nextchar}% \@chnum \if \@nextchar c\z@ \else \if \@nextchar l\@ne \else \if \@nextchar r\tw@ \else \z@ \@chclass \if\@nextchar |\@ne \else \if \@nextchar !6 \else \if \@nextchar @7 \else \if \@nextchar (8 \else \if \@nextchar )9 \else 10 \@chnum \if \@nextchar m\thr@@\else \if \@nextchar p4 \else \if \@nextchar b5 \else \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi} \gdef\arraybackslash{\let\\=\@arraycr} \def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}} \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \def\abbr{} \def\corr{} \def\expan{} \def\gap{} \def\orig{} \def\reg{} \def\ref{} \def\sic{} \def\persName{}\def\name{} \def\placeName{} \def\orgName{} \def\textcal#1{{\fontspec{Lucida Calligraphy}#1}} \def\textgothic#1{{\fontspec{Lucida Blackletter}#1}} \def\textlarge#1{{\large #1}} \def\textoverbar#1{\ensuremath{\overline{#1}}} \def\textquoted#1{‘#1’} \def\textsmall#1{{\small #1}} \def\textsubscript#1{\@textsubscript{\selectfont#1}} \def\textxi{\ensuremath{\xi}} \def\titlem{\itshape} \newenvironment{biblfree}{}{\ifvmode\par\fi } \newenvironment{bibl}{}{} \newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par } \newenvironment{citbibl}{}{\ifvmode\par\fi } \newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi } \newenvironment{docDate}{}{\ifvmode\par\fi } \newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi } \newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par } \newenvironment{msHead}{\vskip 6pt}{\par} \newenvironment{msItem}{\vskip 6pt}{\par} \newenvironment{rubric}{}{} \newenvironment{titlePart}{}{\par } \newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}} \newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}} \newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}} \newcolumntype{P}[1]{){\arraybackslash}p{#1}} \newcolumntype{B}[1]{){\arraybackslash}b{#1}} \newcolumntype{M}[1]{){\arraybackslash}m{#1}} \definecolor{label}{gray}{0.75} \def\unusedattribute#1{\sout{\textcolor{label}{#1}}} \DeclareRobustCommand*{\xref}{\hyper@normalise\xref@} \def\xref@#1#2{\hyper@linkurl{#2}{#1}} \begingroup \catcode`\_=\active \gdef_#1{\ensuremath{\sb{\mathrm{#1}}}} \endgroup \mathcode`\_=\string"8000 \catcode`\_=12\relax \usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry} \usepackage{framed} \definecolor{shadecolor}{gray}{0.95} \usepackage{longtable} \usepackage[normalem]{ulem} \usepackage{fancyvrb} \usepackage{fancyhdr} \usepackage{graphicx} \usepackage{marginnote} \renewcommand{\@cite}[1]{#1} \renewcommand*{\marginfont}{\itshape\footnotesize} \def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif} \pagestyle{fancy} \usepackage[pdftitle={Comparison of the Short-Term Treatment Outcome among Watchful Waiting, and Soluble and Insoluble Corticosteroid Injections in Idiopathic Trigger Finger}, pdfauthor={}]{hyperref} \hyperbaseurl{} \paperwidth210mm \paperheight297mm \def\@pnumwidth{1.55em} \def\@tocrmarg {2.55em} \def\@dotsep{4.5} \setcounter{tocdepth}{3} \clubpenalty=8000 \emergencystretch 3em \hbadness=4000 \hyphenpenalty=400 \pretolerance=750 \tolerance=2000 \vbadness=4000 \widowpenalty=10000 \renewcommand\section{\@startsection {section}{1}{\z@}% {-1.75ex \@plus -0.5ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large\bfseries}} \renewcommand\subsection{\@startsection{subsection}{2}{\z@}% {-1.75ex\@plus -0.5ex \@minus- .2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large}} \renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}% {-1.5ex\@plus -0.35ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\large}} \renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}% {-1ex \@plus-0.35ex \@minus -0.2ex}% {0.5ex \@plus .2ex}% {\reset@font\normalsize}} \renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}% {1.5ex \@plus1ex \@minus .2ex}% {-1em}% {\reset@font\normalsize\bfseries}} \def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt} \@tempdima 1.5em \begingroup \parindent \z@ \rightskip \@pnumwidth \parfillskip -\@pnumwidth \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par \endgroup} \def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}} \def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}} \def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}} \def\l@subparagraph{\@dottedtocline{5}{10em}{5em}} \@ifundefined{c@section}{\newcounter{section}}{} \@ifundefined{c@chapter}{\newcounter{chapter}}{} \newif\if@mainmatter \@mainmattertrue \def\chaptername{Chapter} \def\frontmatter{% \pagenumbering{roman} \def\thechapter{\@roman\c@chapter} \def\theHchapter{\roman{chapter}} \def\thesection{\@roman\c@section} \def\theHsection{\roman{section}} \def\@chapapp{}% } \def\mainmatter{% \cleardoublepage \def\thechapter{\@arabic\c@chapter} \setcounter{chapter}{0} \setcounter{section}{0} \pagenumbering{arabic} \setcounter{secnumdepth}{6} \def\@chapapp{\chaptername}% \def\theHchapter{\arabic{chapter}} \def\thesection{\@arabic\c@section} \def\theHsection{\arabic{section}} } \def\backmatter{% \cleardoublepage \setcounter{chapter}{0} \setcounter{section}{0} \setcounter{secnumdepth}{2} \def\@chapapp{\appendixname}% \def\thechapter{\@Alph\c@chapter} \def\theHchapter{\Alph{chapter}} \appendix } \newenvironment{bibitemlist}[1]{% \list{\@biblabel{\@arabic\c@enumiv}}% {\settowidth\labelwidth{\@biblabel{#1}}% \leftmargin\labelwidth \advance\leftmargin\labelsep \@openbib@code \usecounter{enumiv}% \let\p@enumiv\@empty \renewcommand\theenumiv{\@arabic\c@enumiv}% }% \sloppy \clubpenalty4000 \@clubpenalty \clubpenalty \widowpenalty4000% \sfcode`\.\@m}% {\def\@noitemerr {\@latex@warning{Empty `bibitemlist' environment}}% \endlist} \def\tableofcontents{\section*{\contentsname}\@starttoc{toc}} \parskip0pt \parindent1em \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \newenvironment{reflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemsep}{0pt}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\itshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{sansreflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\itemsep}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\upshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{specHead}[2]% {\vspace{20pt}\hrule\vspace{10pt}% \phantomsection\label{#1}\markright{#2}% \pdfbookmark[2]{#2}{#1}% \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}% }{} \def\TheFullDate{2016-01-15 (revised: 15 January 2016)} \def\TheID{\makeatother } \def\TheDate{2016-01-15} \title{Comparison of the Short-Term Treatment Outcome among Watchful Waiting, and Soluble and Insoluble Corticosteroid Injections in Idiopathic Trigger Finger} \author{}\makeatletter \makeatletter \newcommand*{\cleartoleftpage}{% \clearpage \if@twoside \ifodd\c@page \hbox{}\newpage \if@twocolumn \hbox{}\newpage \fi \fi \fi } \makeatother \makeatletter \thispagestyle{empty} \markright{\@title}\markboth{\@title}{\@author} \renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@ \belowdisplayskip \abovedisplayskip \abovedisplayshortskip \z@ plus2\p@ \belowdisplayshortskip 4\p@ plus2\p@ minus2\p@ \def\@listi{\leftmargin\leftmargini \topsep 2\p@ plus1\p@ minus1\p@ \parsep 2\p@ plus\p@ minus\p@ \itemsep 1pt} } \makeatother \fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm} \fancyhf{} \setlength{\headheight}{14pt} \fancyhead[LE]{\bfseries\leftmark} \fancyhead[RO]{\bfseries\rightmark} \fancyfoot[RO]{} \fancyfoot[CO]{\thepage} \fancyfoot[LO]{\TheID} \fancyfoot[LE]{} \fancyfoot[CE]{\thepage} \fancyfoot[RE]{\TheID} \hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true} \fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}} \date{} \usepackage{authblk} \providecommand{\keywords}[1] { \footnotesize \textbf{\textit{Index terms---}} #1 } \usepackage{graphicx,xcolor} \definecolor{GJBlue}{HTML}{273B81} \definecolor{GJLightBlue}{HTML}{0A9DD9} \definecolor{GJMediumGrey}{HTML}{6D6E70} \definecolor{GJLightGrey}{HTML}{929497} \renewenvironment{abstract}{% \setlength{\parindent}{0pt}\raggedright \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt \textcolor{GJBlue}{\large\bfseries\abstractname\space} }{% \vskip8pt \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt } \usepackage[absolute,overlay]{textpos} \makeatother \usepackage{lineno} \linenumbers \begin{document} \author[1]{Junko Sato} \author[2]{Yoshinori Ishii} \author[3]{Hideo Noguchi} \affil[1]{ } \renewcommand\Authands{ and } \date{\small \em Received: 16 December 2015 Accepted: 2 January 2016 Published: 15 January 2016} \maketitle \begin{abstract} This study aimed to compare the short-term result of local corticosteroid injections in the treatment of idiopathic trigger finger between previously reported proper amount of soluble and insoluble steroids; dexamethasone sodium phosphate and triamcinolone acetonide, and also aimed to compare these results with that of the patients who did not undergo the corticosteroid injection as control group.Methods: Fifty-six patients (16 men and 40 women; age, 38-79 years; mean age, 60.0 ± 8.8 years) who initially diagnosed with idiopathic trigger finger in our clinic were assigned to watchful waiting, local injection of triamcinolone acetonide (insoluble preparation), or that of dexamethasone sodium phosphate (soluble preparation). The examined digits included 30 thumbs and 1 index, 17 middle, and 8 ring fingers. All patients scored the visual analogue scale (VAS), and were graded according to clinical findings at the timing of initial diagnosis and four weeks following the diagnosis. Statistical analyses focused on the difference of the VAS score and clinical grades between initial and the 4-week evaluation in each treatment group, and also on the comparison of these difference among treatment groups. \end{abstract} \keywords{trigger finger; corticosteroid injection; triamci-nolone acetonide; dexamethasone sodium phosphate.} \begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) \textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark} \end{textblock*} \begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) \textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}} \end{textblock*} \let\tabcellsep& \par Abstract-Objectives: This study aimed to compare the shortterm result of local corticosteroid injections in the treatment of idiopathic trigger finger between previously reported proper amount of soluble and insoluble steroids; dexamethasone sodium phosphate and triamcinolone acetonide, and also aimed to compare these results with that of the patients who did not undergo the corticosteroid injection as control group.\par Methods: Fifty-six patients (16 men and 40 women; age, 38-79 years; mean age, 60.0 ± 8.8 years) who initially diagnosed with idiopathic trigger finger in our clinic were assigned to watchful waiting, local injection of triamcinolone acetonide (insoluble preparation), or that of dexamethasone sodium phosphate (soluble preparation). The examined digits included 30 thumbs and 1 index, 17 middle, and 8 ring fingers. All patients scored the visual analogue scale (VAS), and were graded according to clinical findings at the timing of initial diagnosis and four weeks following the diagnosis. Statistical analyses focused on the difference of the VAS score and clinical grades between initial and the 4-week evaluation in each treatment group, and also on the comparison of these difference among treatment groups.\par Results: Whereas the VAS score significantly improved in two injection groups, a significant difference in the improvement of the VAS score and clinical grade was revealed between the group of triamcinolone acetonide and other two groups. We could not find any advantages in the injection of dexamethasone sodium phosphate comparing with watchful waiting.\par Conclusions: The injection of triamcinolone acetonide in idiopathic trigger finger had better short-term outcome when comparing with the injection of dexamethasone sodium phosphate and watchful waiting.\par Keywords: trigger finger; corticosteroid injection; triamcinolone acetonide; dexamethasone sodium phosphate.\par Corticosteroid injections can be easily performed without specialized technique in outpatient clinic; it was reported to have no difference in effectiveness between intrasheath and subcutaneous injections \hyperref[b2]{3} .\par Injectable steroid preparation can be roughly classified into two categories; soluble or insoluble formulations. Soluble forms tend to diffuse rapidly from injection site and to exert a higher degree of systemic effects when compared to insoluble formulations, whereas insoluble forms aggregate to be crystal formation and have theoretical advantage being longer duration of effect \hyperref[b3]{4} . On the other hands, crystal deposits that remain in the tendon sheaths might disrupt smooth gliding, leading to suboptimal function \hyperref[b4]{5} . Treating physician should be also aware of previously reported adverse events including tendon rupture \hyperref[b5]{6} , flare reaction \hyperref[b6]{7} , and the atrophy of subcutaneous fat \hyperref[b7]{8} which are more commonly associated with insoluble steroid injection. Ring et al. randomized 84 patients to receive either triamcinolone (insoluble preparation) or dexamethasone (soluble preparation), and triamcinolone had a more rapid but less durable effect \hyperref[b9]{9} .\par In this study, we aimed to compare the shortterm result of local corticosteroid injections in the treatment of idiopathic trigger finger between previously reported proper amount of soluble and insoluble steroids; dexamethasone sodium phosphate and triamcinolone acetonide. We also aimed to compare these results with that of the patients who did not undergo the corticosteroid injection as control group. \section[{II. Methods}]{II. Methods}\par The institutional review board approved this study protocol. All patients were informed of the study aims and procedures and signed a consent form that included a description of the protocol. During the period from January 2014 to August 2015, consecutive patients clinically diagnosed with idiopathic trigger finger in our clinic were recruited. Patients with multiple trigger fingers, diabetes mellitus, rheumatoid arthritis, dialysis treatment, fingers with a history of local gouty/pyogenic disease, major hand trauma, prior treatment in other I. Introduction orticosteroid injections are commonly used in the management of trigger finger. In general, they have been recognized as considerable first lined treatment before the patients decide to undergo surgery, with the expectation of 60\% effectiveness in relieving pain of idiopathic trigger finger \hyperref[b0]{1,}\hyperref[b1]{2} .\par Author ? ? ?: Ishii Orthopaedic \& Rehabilitation Clinic, 1089 Shimo-Oshi, Gyoda, Saitama 361-0037, Japan. e-mails: jun-sato@hotmail.co.jp, ishii@sakitama.or.jp, hid\textunderscore 166super@mac.com C institute were excluded from this study. Plain radiographs were evaluated in all patients. We confirmed that none of the included patients had a history of trauma, tumors, calcium deposits, or severe osteoarthritis.\par At the time of initial diagnosis, each patient scored the visual analogue scale (VAS) to assess their subjective pain using measuring equipment. Patients were asked to make a mark on a line between the two extremes of complete painless and the maximum pain they could imagine. The distance of entire line was of 100 mm, and the score was measured as the distance between complete painless and the point they marked. In addition, each finger was graded according to clinical findings, resulting in four groups10. Grade I represented a vague sense of tightness and tenderness around the metacarpophalangeal joint, and patients did not exhibit triggering; grade II represented intermittent triggering; grade III represented continuous triggering with or without interphalangeal (IP) joint contracture and locking reduced with active extension; and grade IV represented continuous triggering with or without IP joint contracture. Grade IV patients required passive assist to achieve maximal extension and could not completely flex actively.\par We separated the affected digits into the group of thumb and other digits to equalize the number of each finger in the study cohort using a quasirandomized approach as below. In each group, one of the following treatments was assigned to each affected digit in the order of (1), ( {\ref 2}) and (3) according to the new diagnosis of idiopathic trigger finger, and this process was repeated; (1) watchful waiting without local corticosteroid injection, (2) local injection of the mixed preparation of triamcinolone acetonide (Kenacort-A 50mg/5mL, Bristol-Myers Squibb K.K, Japan) 1mg/0.1mL and 1\% Mepivacaine Hydrochloride (Carbocain Injection 1\%, AstraZeneca K.K, Japan) 0.9mL, (3) local injection of the mixed preparation of dexamethasone sodium phosphate (Orgadrone Injection 1.9mg, MSD K.K, Japan) 3.8mg/1.0mL and 1\% Mepivacaine Hydrochloride (Carbocain Injection 1\%) 0.5mL. With regards to the proper amount of each corticosteroid injection, we referred to the description of previous review article ( Dahl and Hammert, 2012); proper dosages for the small joint such as finger and wrist is 4-10 mg in dexamethasone sodium phosphate, and 0.8-1.0 mg triamcinolone acetonide, respectively. The injections were performed at the timing of initial diagnosis, and placed into and around the flexor sheath using a 27-gauge needle at the level of the A1 pulley. All patients were also recommended joint stretching of the affected digit and activity modification if they had overused their affected hand. They were explained to revisit our clinic for reevaluation with a 4-week interval following the injection regardless of the improvement or exacerbation of their symptoms. In the reevaluation, the same measurement of the VAS score and same clinical grading with initial evaluation were performed. All diagnoses, evaluations and corticosteroid injections were performed by a senior hand surgeon with 15 years of experience in surgery.\par As a result, 56 patients (16 men and 40 women; age, 38-79 years; mean age, 60.0 ± 8.8 years) who actually revisit our clinic at four weeks after initial visit were evaluated in statistical analyses. The examined digits included 30 thumbs and 1 index, 17 middle, and 8 ring fingers.\par We confirmed there was no difference in patients' initial symptom among treatment groups using the Kruskal-Wallis test for the VAS score and Friedman test for the clinical grade, respectively. With regards the treatment outcome, statistical analyses focused on the difference of the VAS score and clinical grades between initial and the 4-week evaluation in each treatment group, and also on the comparison of these difference among treatment groups. On the comparisons among treatment groups, we calculated the improvement of the VAS score using the following formula; [(reevaluated VAS score -initial VAS score) / initial VAS score] x 100 \%, and also classified each digit into three groups according to the change of clinical grade; (1) improved ( {\ref 2}) unchanged (3) exacerbated. Comparisons of the VAS score and the improvement of the VAS score were performed using the Wilcoxon signed-ranks test in each treatment group and using the Kruskal-Wallis test and Sheffe's F test among treatment groups. Comparisons of clinical grades and their changes were performed using the Mann-Whitney U test. Results were deemed significant if P<.05. \section[{III. Results}]{III. Results}\par Table \hyperref[tab_1]{1} presents the patients' demographics and finger information in each treatment group. No patients who had injection revealed steroid-induced adverse event. There was no difference in patients' initial VAS score and clinical grade among treatment groups. Figures \hyperref[fig_1]{1 and 2} present the results of the VAS score and the improvement of the VAS score, respectively. In the groups of triamcinolone acetonide and dexamethasone sodium phosphate, the VAS score significantly improved at the 4-week evaluation. There was a significant difference in the improvement of VAS score between the group of triamcinolone acetonide and other two groups. Table \hyperref[tab_2]{2} presents the result of clinical grading at initial and the 4-week evaluation. At the 4-week evaluation of clinical grade, three digits were improved, 12 digits were unchanged, and three digits were exacerbated in the group of watchful waiting. In the group of triamcinolone acetonide, 15 digits were improved, two digits were unchanged, and no digits were exacerbated. In the group of dexamethasone sodium phosphate, seven digits were improved, nine digits were unchanged, and five digits were exacerbated. With regards to the change of clinical grade, there was a significant difference between the group of triamcinolone acetonide and other two groups (P<.01), and there was no difference between the group of watchful waiting and that of dexamethasone sodium phosphate. A number of the patient and affected digit is described in the box of gender and finger information. The mean value (standard deviation), and value range is described in the upper and lower box of age, respectively. * dominant hand/non dominant hand ** thumb/index finger/middle fingr/ring finger A corresponding number of the affected digit are described in the box. *N/A represents "not applicable". There is no vague sense of tightness and no tenderness around the MP joint, and patients did not exhibit triggering. In this study comparing two corticosteroid injections for idiopathic trigger finger in previously described proper dose, local injection of triamcinolone acedonide was significantly more effective than that of dexamethasone sodium phosphate at the 4-week evaluation. At this point, we could not find any advantages in the injection of dexamethasone sodium phosphate comparing with watchful waiting without injection.\par We have several limitations in this study. First limitation is small number of patients. Secondly, the assignment of treatment was a quasirandomized and control patients did not underwent placebo injection in our study. Third, we did not consider the cost effectiveness and adverse events in each corticosteroid. We deeply recognize that a treatment that is more effective but has higher cost and higher complication rate may not be the best option.\par Local corticosteroid injection has been popular treatment of trigger finger by its simplicity, applicability in an office setting, and low cost \hyperref[b11]{11} . A review of level I and II studies reported one corticosteroid injection were effective in relieving pain in 57\% of the patients with trigger finger1. In the study of long-term follow up in one year of 130 patients with trigger finger who underwent corticosteroid injection of 40mg triamcinolone, younger age, insulin-dependent diabetes mellitus, involvement of multiple digits at the time of injection, and a history of other tendinopathies of the upper extremity were associated with a higher rate of failure; they were all independent predictors of a future surgical release \hyperref[b12]{12} .\par Soluble steroid forms are salt formulations that are freely water-soluble, have a clear, nonparticulate preparation. They tend to diffuse rapidly from injection site and to exert a higher degree of systemic effects when compared to insoluble formulations. Insoluble steroid forms contain esters that cause them to be highly insoluble in water, which causes aggregation and crystal formation. Insoluble compounds require hydrolysis by host esterases to release the active compounds, with the theoretical advantage being longer duration of effect4. In the previous study of short-and middle-term follow up in the 84 patients with idiopathic trigger finger randomly underwent the injection of dexamethasone or triamcinolone \hyperref[b9]{9} , triamcinolone had significantly better absence of triggering rates, clinical grades, and patient satisfaction at the 6-week evaluation but not at the 3-month evaluation. Ring et al included the patients with diabetes and multiple digit involvement in order to increase the generalizability whereas we did not include these patients. In addition, we used dexamethazone sodium phosphate as soluble preparation and triamcinolone acetonide as insoluble preparation. Triamcinolone acetonide is a more potent derivative of triamcinolone, and we used 1 mg triamcinolone acetonide which is smaller amount comparing with the 5-7.5 mg triamcinolone used in the study of Ring et al.\par Insoluble corticosteroids such as triamcinolone acetonide might be more prone to adverse events. The most common side effect is known as post-injection flare, which is thought to be the result of an acute inflammatory response to the injected steroid ester crystals \hyperref[b13]{13,}\hyperref[b14]{14} , and can occur in up to 33\% of patients with trigger finger or de Quervain's disease who underwent extra-articular steroid injection \hyperref[b6]{7} . Subcutaneous atrophy is more commonly associated with insoluble compounds \hyperref[b15]{15} . Direct intratendinous toriamcinolone injection has been associated with tendon rupture, likely due to an inhibitory effect on tenocyte function, and should be avoided \hyperref[b16]{16} . Dexamethasone sodium phosphate is about 5.3 times as potent as triamcinolone acetonide; equivalent dose is 7.5 mg in dexamethasone sodium phosphate and 40 mg in triamcinolone acetonide, respectively \hyperref[b3]{4} . However, the comparison of effectiveness among two different corticosteroid injections and watchful waiting showed better outcome in the injection of triamcinolone acetonide although the current study evaluate only the short-term outcome in four weeks. Small amount of insoluble steroid might be also safe in the current study despite of previous high rate steroid-induced adverse event.\par In conclusion, the injection of triamcinolone acetonide in idiopathic trigger finger had better shortterm outcome when comparing with the injection of dexamethasone sodium phosphate and watchful waiting without injection either on the improvement of patients' pain and triggering. At least, its effectiveness might be expected to continue for four weeks. This information might be useful in the decision of treatment and the choice of steroid preparation. \section[{V. Funding Acknowledgements}]{V. Funding Acknowledgements}\begin{figure}[htbp] \noindent\textbf{1}\includegraphics[]{image-2.png} \caption{\label{fig_0}Figure 1 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{2}\includegraphics[]{image-3.png} \caption{\label{fig_1}Figure 2 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{} \par \begin{longtable}{} \end{longtable} \par \caption{\label{tab_0}}\end{figure} \begin{figure}[htbp] \noindent\textbf{1} \par \begin{longtable}{P{0.23151750972762644\textwidth}P{0.1686770428015564\textwidth}P{0.195136186770428\textwidth}P{0.07937743190661478\textwidth}P{0.06284046692607004\textwidth}P{0.11245136186770428\textwidth}} \tabcellsep \multicolumn{2}{l}{Finger information}\tabcellsep \tabcellsep \tabcellsep \\ \tabcellsep Gender (male/female)\tabcellsep Age (years)\tabcellsep (right/left)\tabcellsep (d/nd)*\tabcellsep (T/I/M/R)**\\ Watichful waiting\tabcellsep 5/13\tabcellsep 58 (SD 8)\tabcellsep 9/9\tabcellsep 10/8\tabcellsep 8/1/7/2\\ \tabcellsep -\tabcellsep (40-73)\tabcellsep \tabcellsep \tabcellsep \\ Triamcinolone acetonide\tabcellsep 4/13\tabcellsep 65 (SD 8)\tabcellsep 11/6\tabcellsep 13/4\tabcellsep 10/0/5/2\\ \tabcellsep \tabcellsep (51-79)\tabcellsep \tabcellsep \tabcellsep \\ Dexamethasone sodium phosphate\tabcellsep 7/14\tabcellsep 58 (SD 9)\tabcellsep 11/10\tabcellsep 12/9\tabcellsep 12/0/5/4\\ \tabcellsep \tabcellsep (38-75)\tabcellsep \tabcellsep \tabcellsep \end{longtable} \par \caption{\label{tab_1}Table 1 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{2} \par \begin{longtable}{P{0.4722222222222222\textwidth}P{0.04722222222222222\textwidth}P{0.09444444444444444\textwidth}P{0.14166666666666666\textwidth}P{0.09444444444444444\textwidth}} Grande\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ N/A*\tabcellsep I\tabcellsep II\tabcellsep III\tabcellsep IV\end{longtable} \par \caption{\label{tab_2}Table 2 :}\end{figure} \footnote{Comparison of the Short-Term Treatment Outcome among Watchful Waiting, and Soluble and Insoluble Corticosteroid Injections in Idiopathic Trigger Finger} \backmatter \par This research received no specific grant from any funding agency in the public, commercial, or notfor-profit sectors. \subsection[{Declaration of Conflicting Interests}]{Declaration of Conflicting Interests}\par All authors declare no conflict of interest in preparing this article. \begin{bibitemlist}{1} \bibitem[ J Bone Joint Surg Am ()]{b8}\label{b8} \textit{}, \textit{J Bone Joint Surg Am} 2007. 89 p. . \bibitem[Ring et al. ()]{b9}\label{b9} ‘A prospective randomized controlled trial of injection of dexamethasone versus triamcinolone for idiopathic trigger finger’. D Ring , S Lozano-Calderón , R Shin . \textit{J Hand Surg Am} 2008. 33 p. . \bibitem[Benzon et al. ()]{b4}\label{b4} ‘Comparison of the particle sizes of different steroids and the effect of dilution: a review of the relative neurotoxicities of the steroids’. H T Benzon , T L Chew , R J Mccarthy . \textit{Anesthesiology} 2007. 106 p. . \bibitem[Kumar and Newman ()]{b14}\label{b14} ‘Complications of intraand peri-articular steroid injections’. N Kumar , R J Newman . \textit{Br J Gen Pract} 1999. 49 p. . \bibitem[Brito and Rozental ()]{b1}\label{b1} ‘Corticosteroid injection for idiopathic trigger finger’. J L Brito , T D Rozental . \textit{J Hand Surg Am} 2010. 35 p. . \bibitem[Baumgarten et al.]{b7}\label{b7} \textit{Corticosteroid injection in diabetic patients with trigger finger. A prospective, randomized, controlled double-blinded study}, K M Baumgarten , D Gerlach , M I Boyer . \bibitem[Taras et al. ()]{b2}\label{b2} ‘Corticosteroid injections for trigger digits: is intrasheath injection necessary?’. J S Taras , J S Raphael , W T Pan . \textit{J Hand Surg Am} 1998. 23 p. . \bibitem[Fleisch et al. ()]{b0}\label{b0} ‘Corticosteroid injections in the treatment of trigger finger: a level I and II systematic review’. S B Fleisch , K P Spindler , D H Lee . \textit{J Am Acad Orthop Surg} 2007. 15 p. . \bibitem[Fitzgerald et al. ()]{b5}\label{b5} ‘Delayed flexor digitorum superficialis and profundus ruptures in a trigger finger after a steroid injection: a case report’. B T Fitzgerald , E P Hofmeister , R A Fan . \textit{J Hand Surg Am} 2005. 30 p. . \bibitem[Goldfarb et al. ()]{b6}\label{b6} ‘Extra-articular steroid injection: early patient response and the incidence of flare reaction’. C A Goldfarb , R H Gelberman , K Mckeon . \textit{J Hand Surg Am} 2007. 32 p. . \bibitem[Berger and Yount ()]{b13}\label{b13} ‘Immediate "steroid flare" from intraarticular triamcinolone hexacetonide injection: case report and review of the literature’. R G Berger , W J Yount . \textit{Arthritis Rheum} 1990. 33 p. . \bibitem[Benson and Ptaszek ()]{b11}\label{b11} ‘Injection versus surgery in the treatment of trigger finger’. L S Benson , A J Ptaszek . \textit{J Hand Surg Am} 1997. 22 p. . \bibitem[Dahl and Hammert ()]{b3}\label{b3} ‘Overview of injectable corticosteroids’. J Dahl , W C Hammert . \textit{J Hand Surg Am} 2012. 37 p. . \bibitem[Lund et al. ()]{b15}\label{b15} ‘Persistent local cutaneous atrophy following corticosteroid injection for tendinitis’. I M Lund , R Donde , E A Knudsen . \textit{Rheumatol Rehabil} 1979. 18 p. . \bibitem[Sato et al. ()]{b10}\label{b10} ‘Sonographic appearance of the flexor tendon, volar plate, and A1 pulley with respect to the severity of trigger finger’. J Sato , Y Ishii , H Noguchi . \textit{J Hand Surg Am} 2012. 37 p. . \bibitem[Wong et al. ()]{b16}\label{b16} ‘Triamcinolone suppresses human tenocyte cellular activity and collagen synthesis’. M W Wong , Y N Tang , S C Fu . \textit{Clin Orthop Relat Res} 2004. (421) p. . \bibitem[Rozental et al. ()]{b12}\label{b12} ‘Trigger finger: prognostic indicators of recurrence following corticosteroid injection’. T D Rozental , D Zurakowski , P E Blazar . \textit{J Bone Joint Surg Am} 2008. 90 p. . \end{bibitemlist} \end{document}